Viral Vector Manufacturing Market

Recombinant Adeno-associated Viral Vectors As Therapeutic Agents To Treat Neurological Disorders

Recombinant adeno-associated virus (rAAV) is obtained from a small human parvovirus with an exceptional safety profile. In addition, this viral vector efficiently transduces and supports long-term transgene appearance in the nervous system. These properties make rAAV a reasonable candidate vector for treating neurological diseases. Indeed, rAAV is currently being used in five early-stage clinical trials for several neurodegenerative diseases. The rAAV is one reasonable choice for early-stage clinical improvement due to its inherent safety outline when used in the nervous system. Very early in the development of rAAV as a viral vector, it was found that this vector is highly effective in the nervous system and largely infects neurons.

PD is a common neurodegenerative disease, second only to Alzheimer's disease, affecting the aging community. PD is characterized by the increasing loss of the neurotransmitter dopamine from the striatum with the accompanying loss of the dopamine-producing cells of the substantia nigra (SN). The emerging awareness of genes involved in familial PD has unrolled the possibility of creating more predictive animal models of PD, and rAAV has performed a role in this endeavor.

Rising Number Of Gene Therapy Patients Is Expected To Drive The Market Growth

Increasing number of patients opting for gene therapy to treat diseases such as cancer, cystic fibrosis, heart disease, diabetes, hemophilia, and AIDS is one of the major factors driving the growth of the market over the forecast period. For instance, According to the World Health Organization, an estimated 17.9 million people die due to cardiovascular diseases worldwide each year. This represents 35% of global deaths. Viral vectors are manufactured using system biology and phonemics to determine the cause of a patient's illness at the molecular level, followed by concentrated medications to address individual patient's illness.

Moreover, viral vectors can reduce the cost of treatment and help decrease repeated administration of medications. The demand for plasmid DNA is growing owing to the increase in gene therapy development. Plasmid DNA is a prerequisite for producing AAV (adeno-associated virus), lentivirus, and other viral vector platforms. Adeno-associated AAV2 vectors carrying the therapeutic gene (RPE65) intra-retinal injection helps in improving the vision of individuals suffering from Liber's Congenital Amaurosis. Gene therapy with viral vectors provides a complete cure to patients affected with genetic disorders and other life-threatening disorders, rather than ease symptoms with other treatments. 

There is an increasing number of clinical studies conducted on viral vector manufacturing, emphasizing the potential of gene therapy to address important medical needs. For instance, As per a research article published in 2019, 'Cancer DNA vaccines: current preclinical and clinical developments and future perspectives, it was estimated that personalized DNA vaccines for the treatment of cancers are the future choice to provide the most appropriate combined therapy by analyzing single patient specificity and biomarkers that can predict the response to a specific agent. Also, as per the data published by the Journal of Gene Medicine, in 2017, approximately 2,600 gene therapy clinical trials are ongoing, have been completed or approved in 36 countries. 

Moreover, the countries where the trials were conducted include the U.S., U.K., Australia, Canada, China, France, Germany, Japan, Switzerland, the Netherlands, and others. The successful launch of viral vector gene therapies and a robust pipeline of such therapies are the key factors contributing to the growth of the global viral vector manufacturing market.

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com